non-targeting control gRNA (BRDN0001145885) Citations (2)

Originally described in: Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9.
Doench JG, Fusi N, Sullender M, Hegde M, Vaimberg EW, Donovan KF, Smith I, Tothova Z, Wilen C, Orchard R, Virgin HW, Listgarten J, Root DE Nat Biotechnol. 2016 Jan 18. doi: 10.1038/nbt.3437. PubMed Journal

---

Articles Citing non-targeting control gRNA (BRDN0001145885)

Articles
Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma. Msaouel P, Malouf GG, Su X, Yao H, Tripathi DN, Soeung M, Gao J, Rao P, Coarfa C, Creighton CJ, Bertocchio JP, Kunnimalaiyaan S, Multani AS, Blando J, He R, Shapiro DD, Perelli L, Srinivasan S, Carbone F, Pilie PG, Karki M, Seervai RNH, Vokshi BH, Lopez-Terrada D, Cheng EH, Tang X, Lu W, Wistuba II, Thompson TC, Davidson I, Giuliani V, Schlacher K, Carugo A, Heffernan TP, Sharma P, Karam JA, Wood CG, Walker CL, Genovese G, Tannir NM. Cancer Cell. 2020 May 11;37(5):720-734.e13. doi: 10.1016/j.ccell.2020.04.002. Epub 2020 Apr 30. PubMed
Neddylation inhibition sensitises renal medullary carcinoma tumours to platinum chemotherapy. Shapiro DD, Zacharias NM, Tripathi DN, Karki M, Bertocchio JP, Soeung M, He R, Westerman ME, Gao J, Rao P, Lam TNA, Jonasch E, Perelli L, Cheng EH, Carugo A, Heffernan TP, Walker CL, Genovese G, Tannir NM, Karam JA, Msaouel P. Clin Transl Med. 2023 May;13(5):e1267. doi: 10.1002/ctm2.1267. PubMed

If you have published an article using this material, please email us at to have your article added to this page.